Statements (61)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
biotechnology company
|
| gptkbp:acquisition |
Rett_syndrome_program_from_the_University_of_Pennsylvania
|
| gptkbp:CEO |
David_Hung
|
| gptkbp:clinicalTrials |
data-driven decisions
metabolic disorders neurodegenerative diseases innovative solutions collaborative efforts movement disorders innovative therapies Phase 1/2 patient-centric approach CNS disorders AXO-AAV-GM1 Phase 1/2 AXO-AAV-GM2 Phase 1/2 AXO-AAV-OPMD Phase 1/2 AXO-Lenti-PD Phase 1/2 gene therapy for neurodegenerative diseases |
| gptkbp:collaborations |
gptkb:University_of_California,_San_Francisco
academic institutions |
| gptkbp:focus |
gene therapies
|
| gptkbp:focus_area |
rare diseases
|
| gptkbp:founded |
2014
|
| gptkbp:founder |
David_Hung
|
| gptkbp:funding |
venture capital
|
| gptkbp:goal |
transform lives of patients
|
| gptkbp:headquarters |
gptkb:New_York_City
|
| https://www.w3.org/2000/01/rdf-schema#label |
Axovant Gene Therapies
|
| gptkbp:investmentFocus |
$100 million
|
| gptkbp:leadership |
experienced team
|
| gptkbp:market |
global
|
| gptkbp:mission |
advance gene therapies
|
| gptkbp:partnerships |
gptkb:Pfizer
pharmaceutical companies research institutions biopharmaceutical companies healthcare_organizations |
| gptkbp:products |
AXO-AAV-GM1
AXO-AAV-GM2 AXO-AAV-OPMD AXO-Lenti-PD |
| gptkbp:regulatoryCompliance |
gptkb:FDA
|
| gptkbp:research_areas |
genetic disorders
neurology gene editing cell therapy |
| gptkbp:research_focus |
neurodegenerative disorders
|
| gptkbp:stockExchange |
gptkb:NASDAQ
|
| gptkbp:supportRole |
experts in neurology
experts in rare diseases experts in biotechnology experts in clinical trials experts in drug development experts in gene editing technology experts in gene therapy experts in gene therapy research experts in patient advocacy experts in regulatory affairs |
| gptkbp:technology |
AAV_vector_technology
|
| gptkbp:tributaryOf |
multiple candidates
|
| gptkbp:vision |
leading gene therapy company
|